Genetically modified non-human animals and methods of use thereof

Patent metadata

Field	Value
Publication number	US-11026408-B2
Application number	US-201916586573-A
Country	US
Kind code	B2
Filing date	Sep 27, 2019
Priority date	Sep 7, 2012
Publication date	Jun 8, 2021
Grant date	Jun 8, 2021

Abstract

The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use.

First claim

The invention claimed is:

1. A method for in vivo evaluation of a vaccine, the method comprising:
administering a vaccine to a genetically modified mouse, wherein the genetically modified mouse comprises in its genome:
a recombination activating gene 2 (Rag-2) gene knock-out,
an IL2 receptor gamma chain (IL2rg) gene knock-out,
a replacement of a mouse M-CSF gene with a nucleic acid encoding a human M-CSF polypeptide at a mouse M-CSF gene locus,
a replacement of a mouse IL-3 gene with a nucleic acid encoding a human IL-3 polypeptide at a mouse IL-3 gene locus,
a replacement of a mouse GM-CSF gene with a nucleic acid encoding a human GM-CSF polypeptide at a mouse GM-CSF gene locus,
a replacement of a mouse TPO gene with a nucleic acid encoding a human TPO polypeptide at a mouse TPO gene locus, and
an insertion of a nucleic acid encoding a human SIRP polypeptide,
wherein each of the nucleic acids encoding the human M-CSF polypeptide, the human IL-3 polypeptide, the human GM-CSF polypeptide, the human SIRP polypeptide, and the human TPO polypeptide is operably linked to a promoter,
wherein the mouse expresses the human M-CSF polypeptide, the human IL-3 polypeptide, the human GM-CSF polypeptide, the human SIRPA polypeptide, and the human TPO polypeptide, and
wherein the mouse is engrafted with human hematopoietic cells; and

assessing an immune response to the vaccine in the genetically modified mouse.

2. The method of claim 1 , wherein the human hematopoietic cells comprise hematopoietic stem cells (HSCs).

3. The method of claim 1 , wherein the human hematopoietic cells comprise hematopoietic stem and progenitor cells (HSPCs).

4. The method of claim 1 , wherein the mouse is not sub-lethally irradiated prior to the engraftment of the human hematopoietic cells.

5. A method for in vivo evaluation of a vaccine, the method comprising:
administering a vaccine to a genetically modified mouse, wherein the genetically modified mouse comprises in its genome:
a recombination activating gene 2 (Rag-2) gene knock-out,
an IL2 receptor gamma chain (IL2rg) gene knock-out,
a replacement of a mouse M-CSF gene with a nucleic acid encoding a human M-CSF polypeptide at a mouse M-CSF gene locus,
a replacement of a mouse IL-3 gene with a nucleic acid encoding a human IL-3 polypeptide at a mouse IL-3 gene locus,
a replacement of a mouse GM-CSF gene with a nucleic acid encoding a human GM-CSF polypeptide at a mouse GM-CSF gene locus,
a replacement of a mouse TPO gene with a nucleic acid encoding a human TPO polypeptide at a mouse TPO gene locus, and
an insertion of a nucleic acid encoding a human SIRP polypeptide,
wherein each of the nucleic acids encoding the human M-CSF polypeptide, the human IL-3 polypeptide, the human GM-CSF polypeptide, the human SIRP polypeptide, and the human TPO polypeptide is operably linked to a promoter,
wherein the mouse expresses the human M-CSF polypeptide, the human IL-3 polypeptide, the human GM-CSF polypeptide, the human SIRPA polypeptide, and the human TPO polypeptide, and
wherein the mouse is engrafted with CD34+human hematopoietic cells and wherein the mouse exhibits a significantly higher proportion of human CD33+myeloid cells in blood and bone marrow relative to a genetically modified mouse engrafted with human CD34+cells which does not express the human M-CSF polypeptide, the human IL-3 polypeptide, the human GM-CSF polypeptide, the human SIRPA polypeptide, and the human TPO polypeptide; and

assessing an immune response to the vaccine in the genetically modified mouse.

6. The method of claim 5 , wherein the mouse is not sub-lethally irradiated prior to the engraftment of the CD34+human hematopoietic cells.

7. A method for testing the effect of an agent that modulates cancer cell growth or survival, or for the in vivo evaluation of a cancer treatment involving the agent, the method comprising:
administering the agent to a genetically modified mouse, wherein the genetically modified mouse comprises in its genome:
a recombination activating gene 2 (Rag-2) gene knock-out,
an IL2 receptor gamma chain (IL2rg) gene knock-out,
a replacement of a mouse M-CSF gene with a nucleic acid encoding a human M-CSF polypeptide at a mouse M-CSF gene locus,
a replacement of a mouse IL-3 gene with a nucleic acid encoding a human IL-3 polypeptide at a mouse IL-3 gene locus,
a replacement of a mouse GM-CSF gene with a nucleic acid encoding a human GM-CSF polypeptide at a mouse GM-CSF gene locus,
a replacement of a mouse TPO gene with a nucleic acid encoding a human TPO polypeptide at a mouse TPO gene locus, and
an insertion of a nucleic acid encoding a human SIRP polypeptide,
wherein each of the nucleic acids encoding the human M-CSF polypeptide, the human IL-3 polypeptide, the human GM-CSF polypeptide, the human SIRP polypeptide, and the human TPO polypeptide is operably linked to a promoter,
wherein the mouse expresses the human M-CSF polypeptide, the human IL-3 polypeptide, the human GM-CSF polypeptide, the human SIRPA polypeptide, and the human TPO polypeptide, and
wherein the mouse is engrafted with human hematopoietic cells and wherein the mouse is engrafted with human cancer cells; and

assessing effect of the agent on cancer cell growth or survival in the genetically modified mouse.

8. The method of claim 7 , wherein the human hematopoietic cells comprise CD34+cells.

9. The method of claim 7 , wherein the human hematopoietic cells comprise hematopoietic stem cells (HSCs).

10. The method of claim 7 , wherein the human hematopoietic cells comprise hematopoietic stem and progenitor cells (HSPCs).

11. The method of claim 7 , wherein the mouse is not sub-lethally irradiated prior to the engraftment of the human hematopoietic cells.

12. The method of claim 7 , wherein the human cancer cells are primary human cancer cells isolated from a patient.

13. The method of claim 12 , wherein the human cancer cells and the human hematopoietic cells are isolated from the same patient.

14. The method of claim 7 , wherein the human cancer cells are from a cancer cell line.

15. The method of claim 7 , wherein the human cancer cells are selected from leukemia cells, breast cancer cells, lung cancer cells, and melanoma cells.

16. The method of claim 7 , wherein the human cancer cells are leukemia cells.

17. The method of claim 7 , wherein the human cancer cells are melanoma cells.

Assignees

• Regeneron Pharma
• Univ Yale
• Institute For Res In Biomedicine Irb

Inventors

• Flavell Richard
• Manz Markus
• Rongvaux Anthony
• Strowig Till
• Willinger Tim
• Murphy Andrew J
• Stevens Sean
• Yancopoulos George

Classifications

• C07K14/5403

  IL-3 · CPC title

• C07K14/4705

  stimulating, promoting or activating activity · CPC title

• A01K67/027

  New or modified breeds of vertebrates · CPC title

• C07K14/70503

  Immunoglobulin superfamily · CPC title

• C07K14/524

  Thrombopoietin, i.e. C-MPL ligand · CPC title